HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

ESLA

Estrella Immunopharma Inc

Last Close
Nov 20  •  04:00PM ET
1.62
Dollar change
-0.13
Percentage change
-7.43 %
Healthcare • Biotechnology • USA • NASD
Peers: MRNA NVAX BNTX PFE JNJ REGN GILD VRTX AZN LLY
 | Held by: VTI VXF IWC
Scroll to Statements
Index- P/E- EPS (ttm)-0.37 Insider Own70.36% Shs Outstand37.77M Perf Week-26.36%
Market Cap61.18M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float11.19M Perf Month-30.47%
Enterprise Value59.55M PEG- EPS next Q-0.19 Inst Own1.97% Short Float0.56% Perf Quarter67.03%
Income-13.50M P/S- EPS this Y- Inst Trans0.73% Short Ratio0.25 Perf Half Y62.00%
Sales0.00M P/B- EPS next Y- ROA-371.99% Short Interest0.06M Perf YTD35.00%
Book/sh-0.26 P/C37.53 EPS next 5Y- ROE-314.60% 52W High3.15 -48.57% Perf Year82.04%
Cash/sh0.04 P/FCF- EPS past 3/5Y-78.83% - ROIC- 52W Low0.73 121.89% Perf 3Y-83.67%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility18.27% 18.38% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-51.97% Oper. Margin- ATR (14)0.35 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.15 Sales Y/Y TTM- Profit Margin- RSI (14)40.29 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.15 EPS Q/Q-38.69% SMA20-30.96% Beta0.62 Target Price16.00
Payout- Debt/Eq- Sales Q/Q- SMA50-8.96% Rel Volume1.17 Prev Close1.75
Employees- LT Debt/Eq- EarningsSep 03 SMA20037.62% Avg Volume248.34K Price1.62
IPOSep 14, 2021 Option/ShortNo / Yes EPS/Sales Surpr.3.43% - Trades Volume289,412 Change-7.43%
Nov-04-25 12:13PM
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?
(Barchart) -24.92%
Nov-03-25 08:00AM
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
(Business Wire) +26.03%
Oct-06-25 08:00AM
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
(Business Wire) +6.87%
Jun-05-25 08:00AM
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
(Business Wire) +7.07%
Jun-03-25 08:00AM
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
(Business Wire) -14.00%
11:15PM Loading…
May-29-25 11:15PM
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
(Insider Monkey) +5.15%
08:01AM
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkins Lymphomas
(Business Wire)
Mar-05-25 08:00AM
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
(Business Wire)
Feb-22-25 08:55AM
Estrella Immunopharma completes first dose cohort in STARLIGHT trial
(TipRanks)
Feb-21-25 08:30AM
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
(Business Wire)
Feb-19-25 04:46PM
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
(Business Wire) +8.76%
Sep-27-24 12:00PM
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells
(Business Wire) +22.69%
Aug-14-24 12:00PM
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
(Business Wire)
Aug-02-24 07:34AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
(InvestorPlace) -18.08%
May-20-24 10:52AM
ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024
(InvestorPlace)
10:34AM Loading…
Sep-29-23 10:34AM
TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination
(PR Newswire) -6.22%
Sep-18-23 05:00PM
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
(PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
(PR Newswire)
Jul-18-23 04:30PM
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
(PR Newswire)
Jul-12-23 07:00AM
TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash
(PR Newswire)
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.